On the evening of October 29, Guangzhou Kingmed Diagnostics Group Co., Ltd. (referred to as "Kingmed Diagnostics") released its third-quarter report for 2025. The company reported Q3 revenue of RMB 1.541 billion, down 11.32% year-over-year (YoY). Net profit attributable to shareholders reached RMB 5.1973 million, marking a 24.08% YoY increase. Adjusted net profit, excluding non-recurring gains and losses, stood at RMB 14 million, surging 264.54% YoY—the first quarterly profit turnaround in 2025.
For the first three quarters, however, Kingmed Diagnostics recorded a net loss of RMB 80 million attributable to shareholders, primarily due to a one-time credit impairment loss of RMB 345 million related to historical issues.
Notably, the company’s operating cash flow improved quarter-over-quarter, reflecting its disciplined cash management and revenue quality strategy. Cost optimization and digital transformation initiatives also yielded results, with gross margins showing sequential growth and operational efficiency improving.
Kingmed Diagnostics emphasized its commitment to long-term growth and innovation, focusing on five strategic pillars: marketing model upgrades, product portfolio strategies, differentiated services, cost leadership, and digital transformation.
Aligned with national policies to expand quality healthcare resources and strengthen county-level medical alliances, Kingmed signed contracts for 21 medical consortium projects in the first three quarters and secured 14 precision共建 projects across infectious diseases, oncology, genetics, and mass spectrometry. The company also enhanced its affordable Huimin System product line, introducing cost-effective solutions in oncology, hematology, infections, and neurology/psychiatry. Examples include optimized tumor screening panels, multi-cancer联合检测, and expanded惠民 offerings to 69 items. By Q3, Huimin System revenue grew 53.8% YoY.
In 2025, healthcare AI models saw explosive growth. As an industry leader in digital transformation, Kingmed launched its "AIINALL" initiative, advancing smart diagnostics. Its proprietary "Yujian Yiyan" model achieved breakthroughs in vertical training, integrating DeepGem’s multimodal genomics capabilities. The AI assistant "Xiaoyu Yi," deployed via mini-programs and hospital HIS systems, reached end-users, logging 5.99 million report interpretations and 140,000 monthly active users by Q3.
Kingmed was also selected as the sole medical institution in China’s first trusted data space pilot, registering six专病 datasets and listing 21 data products across exchanges in Guangzhou, Shanghai, and Beijing. Long-term data partnerships were established with pharmaceutical firms, insurers, IVD companies, and hospitals.
Comments